Next-generation therapies for adrenocortical carcinoma
Copyright © 2020 Elsevier Ltd. All rights reserved..
Almost one decade ago, etoposide, doxorubicin, cisplatin and mitotane (EDP-M) has been established as first-line systemic therapy of metastatic adrenocortical carcinoma (ACC). Although heterogeneous, the prognosis of advanced stage ACC is still poor and novel treatments are urgently needed. This article provides a short summary of current systemic ACC treatment and provides a comprehensive overview of new therapeutic approaches that have been investigated in the past years, including drugs targeting the IGF pathway, tyrosine kinase inhibitors, radionuclide treatment, and immunotherapy. The results of most of these trials were disappointing and we will discuss possible reasons why these drugs failed (e.g. drug interactions with mitotane, disease heterogeneity with exceptional responses in very few patients, and resistance mechanisms to immunotherapy). We then will present potential new drug targets that have emerged from many molecular studies (e.g. wnt/β-catenin, cyclin-dependent kinases, PARP1) that may be the foundation of next-generation therapies of ACC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
Best practice & research. Clinical endocrinology & metabolism - 34(2020), 3 vom: 01. Mai, Seite 101434 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Altieri, Barbara [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 01.01.2021 Date Revised 01.01.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.beem.2020.101434 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM312005407 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM312005407 | ||
| 003 | DE-627 | ||
| 005 | 20231225143456.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.beem.2020.101434 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1039.xml |
| 035 | |a (DE-627)NLM312005407 | ||
| 035 | |a (NLM)32622829 | ||
| 035 | |a (PII)S1521-690X(20)30061-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Altieri, Barbara |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Next-generation therapies for adrenocortical carcinoma |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.01.2021 | ||
| 500 | |a Date Revised 01.01.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Almost one decade ago, etoposide, doxorubicin, cisplatin and mitotane (EDP-M) has been established as first-line systemic therapy of metastatic adrenocortical carcinoma (ACC). Although heterogeneous, the prognosis of advanced stage ACC is still poor and novel treatments are urgently needed. This article provides a short summary of current systemic ACC treatment and provides a comprehensive overview of new therapeutic approaches that have been investigated in the past years, including drugs targeting the IGF pathway, tyrosine kinase inhibitors, radionuclide treatment, and immunotherapy. The results of most of these trials were disappointing and we will discuss possible reasons why these drugs failed (e.g. drug interactions with mitotane, disease heterogeneity with exceptional responses in very few patients, and resistance mechanisms to immunotherapy). We then will present potential new drug targets that have emerged from many molecular studies (e.g. wnt/β-catenin, cyclin-dependent kinases, PARP1) that may be the foundation of next-generation therapies of ACC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a adrenal cancer | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a mitotane | |
| 650 | 4 | |a targeted therapy | |
| 650 | 4 | |a treatment | |
| 650 | 4 | |a tyrosine kinase inhibitors | |
| 650 | 7 | |a Etoposide |2 NLM | |
| 650 | 7 | |a 6PLQ3CP4P3 |2 NLM | |
| 650 | 7 | |a Mitotane |2 NLM | |
| 650 | 7 | |a 78E4J5IB5J |2 NLM | |
| 650 | 7 | |a Doxorubicin |2 NLM | |
| 650 | 7 | |a 80168379AG |2 NLM | |
| 650 | 7 | |a Cisplatin |2 NLM | |
| 650 | 7 | |a Q20Q21Q62J |2 NLM | |
| 700 | 1 | |a Ronchi, Cristina L |e verfasserin |4 aut | |
| 700 | 1 | |a Kroiss, Matthias |e verfasserin |4 aut | |
| 700 | 1 | |a Fassnacht, Martin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Best practice & research. Clinical endocrinology & metabolism |d 2001 |g 34(2020), 3 vom: 01. Mai, Seite 101434 |w (DE-627)NLM113714572 |x 1878-1594 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2020 |g number:3 |g day:01 |g month:05 |g pages:101434 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.beem.2020.101434 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2020 |e 3 |b 01 |c 05 |h 101434 | ||